Lilly Reports Solid Second-Quarter 2009 Results, Raises EP...(2 $1239.7 (3)% $2326.2 $2360.0 ...),Health

Date:7/22/2009

2 $1,239.7 (3)% $2,326.2 $2,360.0 (1)% Cymbalta 744.4 654.4 14% 1,453.7 1,259.5 15% Humalog(R) 477.5 437.9 9% 928.0 845.3 10% Cialis(R) 363.6 362.2 0% 722.4 699.1 3% Gemzar(R) 353.2 440.1 (20)% 721.0 866.3 (17)% Alimta 385.3 275.0 40% 720.6 522.1 38% Evista 251.3 279.8 (10)% 508.2 540.9 (6)% Humulin(R) 248.1 271.4 (9)% 488.7 529.1 (8)% Forteo(R) 203.3 206.6 (2)% 390.7 391.5 0% Strattera(R) 142.8 135.2 6% 301.7 283.2 7% Total Product Sales 5,113.3 5,033.8 2% 10,005.1 9,743.2 3% Collaboration and Other Revenue(1) 179.5 116.6 54% 334.7 214.8 56% -------- -------- -------- -------- Total Revenue(2) $5,292.8 $5,150.4 3% $10,339.8 $9,958.0 4% (1) Collaboration and other revenue is primarily comprised of Erbitux royalties and 50 percent of Byetta's gross margin in the U.S. (2) Total revenue for the second quarter of 2009 includes $114.6 million of Byetta revenue and $99.7 million of Erbitux revenue.

Zyprexa

In the second quarter of 2009, Zyprexa sales totaled $1.203 billion, a decrease of 3 percent compared with the second quarter of 2008. U.S. sales of Zyprexa increased 3 percent to $582.2 million, driven by higher net effective selling prices. Zyprexa sales in international markets decreased 8 percent, to $621.0 million, driven by the unfavorable impact of foreign exchange rates, partially offset by increased demand. Demand outside the U.S. was favorably impacted by the withdrawal of generic competition in Germany
'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine news :

1. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
2. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
3. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
4. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
5. Lilly Declares Third-Quarter Dividend
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Eli Lilly and Company Announces New Drug Discovery Initiative
8. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
9. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
10. Bart Peterson to Join Lilly Leadership Team
11. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration